alirocumab vs fenofibrate
Side-by-side comparison of alirocumab and fenofibrate Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
TriCor, Antara
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Fenofibrate is a medicine that helps lower bad cholesterol and fats (triglycerides) in your blood, while raising good cholesterol.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
This medicine is used with a diet to treat high cholesterol and high levels of triglycerides (fats) in the blood. It helps adults who have primary hypercholesterolemia or mixed dyslipidemia. It can also treat adults with severe hypertriglyceridemia. However, fenofibrate has not been proven to prevent heart disease in people with type 2 diabetes.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Fenofibrate is a type of drug called a PPAR alpha agonist. It works by activating a protein in your body that helps break down fats and cholesterol. This leads to lower levels of bad cholesterol and triglycerides, and higher levels of good cholesterol.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Abnormal liver function tests
- • Increased ALT (a liver enzyme)
- • Increased AST (a liver enzyme)
- • Increased CPK (a muscle enzyme)
- • Runny nose
- Muscle pain 1,655
- Missed dose 1,364
- Pain at injection site 1,278
- Muscle spasms 1,162
- Joint pain 1,053
- Feeling sick to your stomach 2,914
- Feeling tired 2,842
- Loose or watery stools 2,681
- The medicine is not working 2,450
- Difficulty breathing 2,100
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
Fenofibrate can cause liver problems. Your doctor should check your liver function with blood tests before you start taking it and regularly while you are taking it. Stop taking fenofibrate and tell your doctor right away if you have signs of liver problems, such as yellowing of your skin or eyes, dark urine, or stomach pain. Fenofibrate can also cause muscle pain or weakness, especially if you are also taking a statin medicine. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
It is not known if fenofibrate will harm an unborn baby. You should only use fenofibrate during pregnancy if your doctor decides that the benefit outweighs the risk. You should not breastfeed while taking fenofibrate.
Also Compare — Nearby Drugs
Compare alirocumab with
Compare fenofibrate with
How to Read This alirocumab vs fenofibrate Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while fenofibrate sits within the Fibrate class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while fenofibrate has 12,987. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between alirocumab and fenofibrate — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.